LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Illumina Inc

Suletud

SektorTervishoid

83.64 3.28

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

80

Max

84

Põhinäitajad

By Trading Economics

Sissetulek

-56M

131M

Müük

-63M

1B

Aktsiakasum

0.97

Kasumimarginaal

12.584

Töötajad

8,970

EBITDA

55M

284M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+37.47% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. aug 2025

Turustatistika

By TradingEconomics

Turukapital

-3.4B

13B

Eelmine avamishind

80.36

Eelmine sulgemishind

83.64

Uudiste sentiment

By Acuity

13%

87%

12 / 382 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bullish Evidence

Illumina Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

11. märts 2025, 09:18 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Tesla, Oracle, Delta, Nvidia -- WSJ

10. märts 2025, 21:07 UTC

Peamised uudised

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

10. märts 2025, 20:01 UTC

Peamised uudised

Illumina to Cut $100 Million in Costs, Lowers Guidance Because of China Sales Ban -- WSJ

4. märts 2025, 10:56 UTC

Kuumad aktsiad

Stocks to Watch Tuesday: Illumina, Nvidia, Stellantis -- WSJ

Võrdlus sarnastega

Hinnamuutus

Illumina Inc Prognoos

Hinnasiht

By TipRanks

37.47% tõus

12 kuu keskmine prognoos

Keskmine 111.21 USD  37.47%

Kõrge 185 USD

Madal 75 USD

Põhineb 20 Wall Streeti analüütiku instrumendi Illumina Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

20 ratings

9

Osta

9

Hoia

2

Müü

Tehniline skoor

By Trading Central

77.61 / N/AToetus ja vastupanu

Lühikene perspektiiv

Strong Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

12 / 382 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.